

# 中国创新药研发：现状与未来

## **Innovative Drug R&D in China**

**By Jim J. Zhang, Ph.D.**

**October, 2009**

# Table of Contents

## Scope of the Report

## About Author

## Executive Summary

Current state of innovative drug R&D in China

Chinese companies conducting innovative drug R&D

Innovative drugs in development pipelines of Chinese drug companies

Future prospect of innovative drug R&D in China

## Chapter 1. Current State of Innovative Drug R&D in China

### Summary

#### 1.1 Introduction

#### 1.2 Innovative drug R&D in China: Possible?!

1.2.1 The lost history of innovative drug R&D in China

1.2.2 R&D activities on innovative medicines do exist in China now

1.2.3 Examples of Western pharma companies licensing drug candidates from China

#### 1.3 Current state of innovative drug R&D in China's pharma-related industries

1.3.1 Innovative drug R&D in Chinese pharma and biotech industries

1.3.2 Innovative drug R&D in state-owned research institutions

#### 1.4 Current state of R&D on traditional Chinese medicines (TCM)

#### 1.5 Current capability of China's innovative drug R&D

1.5.1 China's general capability in pharmaceutical research

1.5.2 Capability of Chinese companies in innovative drug R&D

1.5.3 Capability of Chinese companies in development of new drug delivery technologies

1.5.4 Key strengths of Chinese drug companies in innovative drug R&D

1.5.5 Current situation of patent applications in China for innovative drugs

#### 1.6 Current funding sources for innovative drug R&D in China

1.6.1 Initial public offering (IPO)

1.6.2 Self-funded

1.6.3 Venture capitals

1.6.4 Government grants

#### 1.7 Importance of China's innovative drug R&D to the world pharma industry

1.7.1 Western pharma companies desperately need novel drugs to fill out their product pipelines

1.7.2 Novel drug candidates discovered and developed by Chinese companies could become alternative resources to Western companies

1.7.3 Financial crisis has enhanced the importance of China's innovative drug R&D to Western companies

## Chapter 2. Chinese Companies Conducting Innovative Drug R&D

## Summary

### 2.1 Introduction

### 2.2 Searching and selection criteria

### 2.3 Analysis of Chinese companies conducting innovative drug R&D

#### 2.3.1 Business nature of the companies conducting innovative drug R&D in China

#### 2.3.2 Experience of Chinese companies in innovative drug R&D

#### 2.3.3 Analysis of financial support of all China-based innovative drug R&D companies

#### 2.3.4 Analysis of physical locations of innovative drug R&D companies in China

### 2.4 Analysis of product pipelines of all Chinese companies conducting innovative drug R&D

#### 2.4.1 Listing of product pipelines of Chinese drug companies

#### 2.4.2 Analysis of product pipelines of Chinese drug companies

1. Distributions of drug candidates in various development stages in each group of companies
2. Distributions of innovative drug R&D companies focusing on small molecule drugs and macro compound-based drugs
3. Which companies own the most drug candidates
4. Analysis of innovative drug R&D companies according to therapeutic areas

## **Chapter 3. Innovative Drugs in Development Pipelines of Chinese Drug Companies**

### Summary

#### 3.1 Introduction

#### 3.2 Analysis of development stages of drug candidates in the product pipelines of Chinese drug companies

##### 3.2.1 Distributions of development stages of all drug candidates

##### 3.2.2 Detailed listing of all drug candidates in each development stage

#### 3.3 Analysis of molecular structures of all drug candidates in development pipelines

##### 3.3.1 Distributions of all drug candidates of different types of molecular structure

##### 3.3.2 Detailed listing of drug candidates according to their molecular structure

#### 3.4 Analysis of drug candidates in each therapeutic area

##### 3.4.1 Analysis of drug candidates according to their therapeutic functions

##### 3.4.2 Analysis of drug candidates in each therapeutic area according to their development stages

##### 3.4.3 Detailed listing of drug candidates in each therapeutic area

## **Chapter 4. Future Prospect of Innovative Drug R&D in China**

### Summary

#### 4.1 Introduction

#### 4.2 Drivers of future development of innovative drug R&D in China

##### 4.2.1 Attraction of China as one of the world largest pharmaceutical markets

1. Future development potentials of Chinese pharmaceutical market

2. Future market growth potentials of some key therapeutic areas
  - a. Market growth potential of anticancer drugs in China
  - b. Market growth potential of various vaccines in China
3. Key future growth drivers of Chinese pharmaceutical market
  - a. On-going nationwide healthcare reform
  - b. Westernization of living style has changed disease patterns
  - c. Growing middle class population that are able to afford high-end medicines
  - d. Rapid urbanization makes more Chinese able to afford high-end medicines
- 4.2.2 Government encouragement and support for innovative drug R&D
- 4.2.3 Increasing sources and availabilities of R&D funding
  1. Various funding sources from government agencies
  2. Increasing opportunities of venture capital (VC) investment
- 4.2.4 Gradual establishment of exit channels for investment
- 4.2.5 Advantages of conducting innovative drug R&D in China
  1. Rich natural products
  2. A large, treatment-naïve patient pool
  3. Abundant animal species
  4. Large, well-trained workforce
- 4.2.6 Entrance of multinational companies
- 4.2.7 Collaborations between local Chinese drug R&D companies/organizations and between Chinese companies and experienced international drug companies
- 4.2.8 Summary of the future growth drivers of innovative drug R&D in China and analysis of the roles each of them will play
- 4.3 Latest development in other frontier pharmaceutical research in China
  - 4.3.1 Development of novel molecular diagnostic tools and biomarkers
  - 4.3.2 Stem cell research
- 4.4 Existing issues in China's innovative drug R&D
- 4.5 The future perspective of China's innovative drug R&D

### **List of Tables**

- Table 1. Representative state-owned research institutes in life science
- Table 2. Representative state key labs in life science
- Table 3. Representative top research universities having life science schools/colleges
- Table 4. Products under development in Chinese biotech companies using new drug delivery/formulation techniques
- Table 5. List of representative companies/research organizations in China conducting innovative drug R&D
- Table 6. Classifications and distributions of China-based innovative drug R&D companies
- Table 7. Years of innovative drug R&D experience of Chinese companies
- Table 8. Classifications of founders of Chinese companies conducting innovative drug

## R&D

- Table 9. Innovative drug R&D companies founded by returnees or Chinese scholars
- Table 10. Analysis of funding sources of China-based drug R&D companies
- Table 11. Analysis of locations of China-based innovative drug R&D companies
- Table 12. Major Chinese pharma companies conducting innovative drug R&D and their product pipelines
- Table 13. Chinese biotech companies conducting innovative drug R&D and their product pipelines
- Table 14. State-owned research institutes conducting innovative drug R&D and their product pipelines
- Table 15. Chinese CROs conducting innovative drug R&D and their product pipelines
- Table 16. Analysis of drug product pipelines in each group of innovative drug R&D companies
- Table 17. Analysis of the numbers of the innovative drug R&D companies in each drug development stage
- Table 18. Analysis of molecular structure of drug candidates in each group of Chinese companies conducting innovative drug R&D
- Table 19. Top 10 companies having most innovative drug candidates
- Table 20. Analysis and distributions of innovative drug R&D companies according to therapeutic areas
- Table 21. China-based Innovative drug R&D companies having cancer drugs in various development stages
- Table 22. China-based innovative drug R&D companies having anti-viral drugs in various development stages
- Table 23. Analysis of the numbers of drug candidates in each development stage
- Table 24. Drug candidates in preclinical development
- Table 25. Drug candidates in phase I development
- Table 26. Drug candidates in phase II (IIa/IIb) development
- Table 27. Drug candidates in phase III development
- Table 28. Drugs approved or waiting for approval
- Table 29. Classifications and distributions of drug candidates according to their molecular structures
- Table 30. Distributions of small molecule drugs in various development stages
- Table 31. Distributions of macro compound-based drugs in various development stages
- Table 32. List of small molecule drugs in various development stages
- Table 33. List of macro compound-based drugs in various development stages
- Table 34. List of vaccines in development for different purposes
- Table 35. List of new TCMs in development
- Table 36. Distributions of drug candidates in each therapeutic area
- Table 37. Summary of the mechanisms of action of all cancer drugs in development
- Table 38. Numbers of drugs in various development stages of each therapeutic area
- Table 39. Drug candidates in development for cancer
- Table 40. Drug candidates in development for anti-viral diseases
- Table 41. Drug candidates in development for cardiovascular diseases
- Table 42. Anti-biotic drugs in development
- Table 43. Drug candidates in development for metabolic diseases

- Table 44. Drug candidates in development for inflammatory diseases  
 Table 45. Drug candidates in development for CNS diseases  
 Table 46. Drug candidates in development for COPD  
 Table 47. Drug candidates in development for all other diseases  
 Table 48. Current Chinese pharmaceutical market and its future growth forecasts  
 Table 49. Representative venture capital investors in China  
 Table 50. Examples of recent investment activities of Western VCs in China  
 Table 51. Analysis of the roles of growth drivers in determining the future development of China's innovative drug R&D  
 Table 52. Diagnostic products under development  
 Table 53. Stem cell research in China

### **List of Figures**

- Figure 1. Distributions of different types of innovative drug R&D companies in China  
 Figure 2. Distributions of innovative drug R&D companies in term of the years of their research experience  
 Figure 3. Graphic display of funding sources of China-based innovative drug R&D companies  
 Figure 4. Location distributions of innovative drug R&D companies in China  
 Figure 5. Distributions of the number of drug candidates and their development stages in each group of companies  
 Figure 6. Distributions of companies in each development stage of drug R&D  
 Figure 7. Comparison of the numbers between small molecule drugs and macro compound drugs in each group of innovative drug R&D companies  
 Figure 8. Company distributions in each therapeutic area  
 Figure 9. Distributions of development stages of all drug candidates  
 Figure 10. Comparison of the numbers between small molecule drugs and macro compound-based drugs in development pipelines  
 Figure 11. Distributions of small molecule drugs in various development stages  
 Figure 12. Distributions of macro compound-based drugs in various development stages  
 Figure 13. Numbers of drug candidates in each therapeutic area  
 Figure 14. Distributions of drug product pipelines in each therapeutic area  
 Figure 15. Development of Chinese pharmaceutical market: Past, present and future  
 Figure 16. Current market value and forecasted future growth of cancer drug market in China  
 Figure 17. Current market value and forecasted future growth of vaccine market in China  
 Figure 18. Major Western pharma and biotech companies conducting innovative drug R&D in China

### **List of Case Studies**

- Case study 1. Chinese biotech company focusing on development of new drug delivery technologies  
 Case study 2. Example of application for Chinese patent by international drug companies  
 Case study 3. Example of patent application by Chinese company for new formulation of

existing drugs

Case study 4. GSK looking at the Chinese vaccine market

Case study 5. Latest announcement of more R&D funding by Beijing Municipal Government

Case study 6. Latest announcement by Shanghai Municipal Government for availability of new R&D funding

Case study 7. The interest of major Western pharma companies in natural products derived from medicinal herbs of TCMs

Case study 8. Collaboration between Chinese drug company and research institution on innovative drug R&D

Case study 9. R&D collaboration between a Chinese pharma company and a US biotech company

Case study 10. Chinese research institute collaborating with a US-based non-profit organization on development of novel anti-TB agents

Case study 11. Chinese pharma company establishing R&D centers in the Western countries

Case study 12. Chinese company developing diagnostic tools for detection of early stage bladder cancer

### **Company Profile**

Company profiles of 40 Chinese companies conducting innovative drug R&D

### **Appendix**

Appendix I. Research methodology

Appendix II. About JZMed